SCHEMBL322335

SCHEMBL322335

COC(=O)c1cc(C(=O)c2c(-c3ccccc3)c(OC)c3ccccn23)ccc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.45
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
PPARG P37231 3/20 0.45
NCOR2 Q9Y618 3/20 0.45
KDM4E B2RXH2 2/20 0.45
NR2E3 Q9Y5X4 2/20 0.45
PABPC1 P11940 1/20 0.45
TDP1 Q9NUW8 2/20 0.45
LMNA P02545 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 1/20 0.39
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4521306 0.93 MAPT (0.40) MAPTALDH1A1MEN1KMT2APPARG
SCHEMBL4514108 0.92 MAPT (0.40) MAPTALDH1A1MEN1KMT2APPARG
SCHEMBL13918696 0.87 MAPT (0.53) MAPTALDH1A1MEN1KMT2APPARG
SCHEMBL3597910 0.87 MAPT (0.47) MAPTTP53SMN1; SMN2
SCHEMBL321257 0.87 MAPT (0.43) MAPTALDH1A1MEN1KMT2APPARG
SCHEMBL1573132 0.86 MAPT (0.40) MAPTTP53
SCHEMBL1572852 0.85 MAPT (0.42) MAPTTP53SMN1; SMN2
SCHEMBL4508517 0.84 MAPT (0.38) MAPTALDH1A1MEN1KMT2APPARG
SCHEMBL4499233 0.83 MAPT (0.36) MAPTALDH1A1MEN1KMT2APPARG
SCHEMBL27737744 0.80 MAPT (0.46) MAPTALDH1A1MEN1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 MAPT 961/4885ALDH1A1 3536/4885MEN1 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.